Sign In
test

ROBERT J. WENZEL

Aisling Capital Management Lp

Assets Managed
$476.289M
Holdings
13
Last Quarter
2026 - Q1
Filed Date
21d ago
Growth Rate
-0.54%(2Q avg: 2.19%)
Sustained Growth
0 quarters

Portfolio positions

This chart displays the top 10 holdings in Aisling Capital Management Lp's 2026 - Q1 portfolio, based on their 13F SEC filing, out of a total of 13 positions.

Assets under management

The assets under management (AUM) of Aisling Capital Management Lp over the past 10 years (40 quarters) show continuous growth in total asset value over the last 0 quarters. As of the latest 13F SEC filing for 2026 - Q1, they manage 476.289M in assets, with a quarterly growth rate of -0.54% and a 2-quarter average growth rate of 2.19%. The portfolio is managed by ROBERT J. WENZEL, and others.

Portfolio holdings

InvestmentPortfolio %Reported Value
BBIO
Bridgebio Pharma Inc
Recent Activity
79.36%
$377.955M
5.09M shares@ $74.27 avg price
SNDX
Syndax Pharmaceuticals Inc
Recent Activity
6.46%
$30.761M
1.317M shares@ $23.36 avg price
GLUE
Monte Rosa Therapeutics Inc
Recent Activity
Increased 5.66%
5.38%
$25.591M
1.556M shares@ $16.46 avg price
BCAX
Bicara Therapeutics Inc
Recent Activity
2.38%
$11.316M
568,919 shares@ $19.9 avg price
BBOT
Bridgebio Oncology Therapeut
Recent Activity
Increased 80.3%
1.92%
$9.111M
1.018M shares@ $8.95 avg price
CMPS
Compass Pathways Plc
Recent Activity
Increased 19.52%
1.67%
$7.921M
1.432M shares@ $5.53 avg price
SRRK
Scholar Rock Holding Corp
Recent Activity
0.8%
$3.787M
77,031 shares@ $49.17 avg price
BMEA
Biomea Fusion Inc
Recent Activity
0.66%
$3.135M
2.049M shares@ $1.53 avg price
EPRX
Eupraxia Pharmaceuticals Inc
Recent Activity
New Position
0.5%
$2.353M
325,000 shares@ $7.24 avg price
URGN
Urogen Pharma Ltd
Recent Activity
0.41%
$1.942M
108,000 shares@ $17.98 avg price

1-10 of 13